Healthcare services company Astrana Health will be announcing earnings results this Thursday afternoon. Here’s what you need to know.
Astrana Health missed analysts’ revenue expectations by 2.5% last quarter, reporting revenues of $620.4 million, up 53.4% year on year. It was a slower quarter for the company, with revenue guidance for next quarter meeting analysts’ expectations and full-year EBITDA guidance missing analysts’ expectations.
Is Astrana Health a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Astrana Health’s revenue to grow 31.1% year on year to $637.4 million, slowing from the 39.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.48 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Astrana Health has missed Wall Street’s revenue estimates three times over the last two years.
Looking at Astrana Health’s peers in the healthcare technology segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Omnicell delivered year-on-year revenue growth of 5%, beating analysts’ expectations by 4.9%, and Hims & Hers Health reported revenues up 72.6%, falling short of estimates by 1.1%. Omnicell’s stock price was unchanged after the resultswhile Hims & Hers Health was down 12.5%.
Read our full analysis of Omnicell’s results here and Hims & Hers Health’s results here.
Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare technology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Astrana Health’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $45.22 (compared to the current share price of $24.34).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
